Pharmadrug Financial Statements From 2010 to 2025

LMLLF Stock  USD 0.01  0.0009  8.91%   
Pharmadrug financial statements provide useful quarterly and yearly information to potential Pharmadrug investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pharmadrug financial statements helps investors assess Pharmadrug's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pharmadrug's valuation are summarized below:
Pharmadrug does not presently have any trending fundamental ratios for analysis.
Check Pharmadrug financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmadrug's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pharmadrug financial statements analysis is a perfect complement when working with Pharmadrug Valuation or Volatility modules.
  
This module can also supplement various Pharmadrug Technical models . Check out the analysis of Pharmadrug Correlation against competitors.

Pharmadrug Company Return On Asset Analysis

Pharmadrug's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Pharmadrug Return On Asset

    
  -0.19  
Most of Pharmadrug's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmadrug is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Pharmadrug has a Return On Asset of -0.1883. This is 97.85% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 34.5% higher than that of the company.

Pharmadrug Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pharmadrug's current stock value. Our valuation model uses many indicators to compare Pharmadrug value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmadrug competition to find correlations between indicators driving Pharmadrug's intrinsic value. More Info.
Pharmadrug is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmadrug's earnings, one of the primary drivers of an investment's value.

About Pharmadrug Financial Statements

Pharmadrug stakeholders use historical fundamental indicators, such as Pharmadrug's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharmadrug investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharmadrug's assets and liabilities are reflected in the revenues and expenses on Pharmadrug's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharmadrug. Please read more on our technical analysis and fundamental analysis pages.
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Currently Active Assets on Macroaxis

Other Information on Investing in Pharmadrug Pink Sheet

Pharmadrug financial ratios help investors to determine whether Pharmadrug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmadrug with respect to the benefits of owning Pharmadrug security.